Chemotherapeutic agents are cytotoxic drugs that kill or inhibit the proliferation of cancer cells, primarily by interfering with DNA synthesis, replication, and cell division. Despite the advent of targeted therapies and immunotherapies, traditional chemotherapy remains a cornerstone of cancer treatment for many malignancies, used alone or in combination regimens.
What Are Chemotherapeutic Agents?
Chemotherapy exploits the more rapid division of cancer cells compared to most normal tissues. However, this selectivity is relative, and rapidly dividing normal cells including bone marrow, gastrointestinal epithelium, and hair follicles are also affected, accounting for the characteristic toxicity profile of chemotherapy. Combination chemotherapy uses drugs with different mechanisms of action to maximize cell kill, overcome resistance, and share toxicities to allow adequate dosing.
Mechanism of Action
Alkylating agents such as cyclophosphamide, ifosfamide, and busulfan form covalent bonds with DNA, primarily at guanine bases, causing DNA crosslinking and strand breaks that prevent replication and trigger apoptosis. They are cell cycle phase nonspecific and are active against both rapidly dividing and slow-growing tumors. The price of this broad activity is significant myelosuppression and increased risk of secondary malignancies, particularly leukemia.
Antimetabolites interfere with essential metabolic pathways for nucleotide synthesis. Methotrexate inhibits dihydrofolate reductase, depleting reduced folate necessary for thymidylate and purine synthesis. 5-Fluorouracil inhibits thymidylate synthase, blocking DNA synthesis. Cytarabine inhibits DNA polymerase after incorporation into DNA. These agents are S-phase specific, targeting cells actively engaged in DNA synthesis, which makes them particularly effective in rapidly proliferating hematological malignancies.
Plant alkaloids include vinca alkaloids and taxanes, which disrupt microtubule function essential for mitosis. Vinca alkaloids such as vincristine and vinblastine bind to tubulin and prevent microtubule polymerization, arresting cells in metaphase. Taxanes such as paclitaxel and docetaxel promote microtubule polymerization and stabilize microtubules, preventing their disassembly and blocking mitotic progression.
Platinum drugs such as cisplatin, carboplatin, and oxaliplatin form DNA crosslinks through platinum-DNA adducts, similar to alkylating agents. Cisplatin is highly effective in testicular, ovarian, and head and neck cancers but causes significant nephrotoxicity, ototoxicity, and neurotoxicity that require careful monitoring and preventive measures.
Therapeutic Uses
Chemotherapy is used with curative intent in hematological malignancies such as acute lymphoblastic leukemia, Hodgkin lymphoma, and testicular germ cell tumors. In solid tumors, chemotherapy is used in the neoadjuvant setting to shrink tumors before surgery, adjuvantly to eliminate micrometastatic disease, or palliatively to improve symptoms and prolong survival in advanced disease.
Adverse Effects
Myelosuppression is the most frequent dose-limiting toxicity, causing neutropenia, anemia, and thrombocytopenia with increased infection and bleeding risk. Gastrointestinal toxicity includes nausea, vomiting, mucositis, and diarrhea. Alopecia is common with many regimens. Specific toxicities include cisplatin nephrotoxicity, doxorubicin cardiotoxicity, bleomycin pulmonary fibrosis, and cyclophosphamide hemorrhagic cystitis. Nausea and vomiting are managed with antiemetic regimens including 5-HT3 antagonists and neurokinin-1 receptor antagonists.
Contraindications
Chemotherapy is contraindicated in patients with severe bone marrow suppression, active infection, and significant organ dysfunction that would prevent clearance of the drugs. Dose adjustments are required for hepatic and renal impairment. Pregnancy is an absolute contraindication due to teratogenicity.
Conclusion
Traditional chemotherapeutic agents remain essential in oncology despite their narrow therapeutic index. Supportive care advances have substantially improved tolerability, and rational combination regimens continue to evolve based on tumor biology and mechanisms of drug resistance.
